XML 42 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 05, 2023
Dec. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2026
Dec. 31, 2025
Dec. 31, 2024
Mar. 20, 2025
Nov. 30, 2024
Jun. 27, 2024
Dec. 01, 2020
Revenue from Contract with Customer, Excluding Assessed Tax     $ 393,572 $ 334,617              
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer     0                
Alphazyme [Member]                      
Proceeds from Sale, Maturity and Collection of Investments       60,977     $ 1,300,000        
Alphazyme [Member]                      
Ownership Percentage                     1.99%
Research and Development [Member]                      
Revenue from Contract with Customer, Excluding Assessed Tax     183,100 $ 334,617              
Gates Foundation [Member]                      
Accounts Receivable, after Allowance for Credit Loss                 $ 3,092,136    
Proceeds From Grant   $ 800,000                  
Revenue from Contract with Customer, Excluding Assessed Tax     176,000                
Cost of Revenue     143,000                
Gates Foundation [Member] | Forecast [Member]                      
Proceeds From Grant         $ 700,000 $ 1,500,000          
CEPI [Member]                      
Revenue from Contract with Customer, Excluding Assessed Tax     34,000                
Cost of Revenue     28,000                
Grant Receivable               $ 2,400,000      
CEPI [Member] | Fondazione Biotecnopolo di Siena (FBS) [Member]                      
Grant Receivable               $ 4,500,000      
Proliant Agreement [Member]                      
License and Development, Initial Term (Year)                   10 years  
License and Development, Extension Term (Year)                   3 years  
Initial Up Front Payment                   $ 500,000  
Second Payment Upon Completion Transfer                   500,000  
Final Payment Upon Meeting Certain Productivity Threshold                   $ 500,000  
Deferred License Revenue             3,000,000        
Inzymes Agreement APS [Member]                      
Deferred License Revenue             890,169        
Non-refundable Upfront Payment, Received $ 600,000                    
Inzymes Agreement APS [Member] | Research and Development [Member]                      
Revenue from Contract with Customer, Excluding Assessed Tax             $ 25,000        
A Global Food Ingredient Company [Member]                      
Revenue from Contract with Customer, Excluding Assessed Tax     $ 0